Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Corvus Pharmaceuticals Inc shares valued at $4,891,894 were sold by ORBIMED ADVISORS LLC on Jun 27 ’25. At $4.16 per share, ORBIMED ADVISORS LLC sold 1,176,332 shares. The insider’s holdings dropped to 7,165,006 shares worth approximately $29.59 million following the completion of this transaction.
Also, Thompson Peter A. sold 1,176,332 shares, netting a total of over 4,891,894 in proceeds. Following the sale of shares at $4.16 each, the insider now holds 7,165,006 shares.
As published in their initiating research note from H.C. Wainwright on January 02, 2025, Corvus Pharmaceuticals Inc [CRVS] has been a Buy and the price target has been revised to $11. Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid August. Earlier on May 27, 2021, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for CRVS stock.
Analyzing CRVS Stock Performance
On last trading session, Corvus Pharmaceuticals Inc [NASDAQ: CRVS] plunged -0.96% to $4.13. The stock’s lowest price that day was $4.0546, but it reached a high of $4.24 in the same session. During the last five days, there has been a drop of approximately -0.96%. Over the course of the year, Corvus Pharmaceuticals Inc shares have jumped approximately 46.45%.
Is Corvus Pharmaceuticals Inc subject to short interest?
Stocks of Corvus Pharmaceuticals Inc saw a sharp rise in short interest on 2025-07-15 jumping by 1.04 million shares to 8.98 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 7.94 million shares. A jump of 11.63% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.49 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.49.
Which companies own the most shares of Corvus Pharmaceuticals Inc (CRVS)?
In terms of Corvus Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 11 in the next 12 months, up nearly 163.79% from the previous closing price of $4.17. Analysts anticipate Corvus Pharmaceuticals Inc stock to reach 11 by 2025, with the lowest price target being 11. In spite of this, 1 analysts ranked Corvus Pharmaceuticals Inc stock as Buy at the end of 2025. On February 10, 2021, Mizuho assigned a price target of “a Neutral” to the stock and downgraded coverage with a $4.
